Bruker • Microbiology & Infection Diagnostics’ Post

Accelerate your cell line development with Sartorius 🧬🧫🔬 In the fast-paced world 🌎 of #biopharmaceutical #research and development, optimizing #celllinedevelopment is crucial for accelerating #drugdiscovery and production. At Sartorius, we understand the importance of #streamlining workflows and maximizing efficiency. Our iQue Instrument empowers #researchers and biopharmaceutical companies to achieve faster, more reliable results via: - 🧪 High-Throughput Screening - 📊 Multiparametric Analysis - 💡 Customizable Assays - 🔬 Real-time Data Analysis - 💻 Seamless Integration Join us in revolutionizing cell line development with the iQue Instrument! Experience the power of advanced screening and analysis capabilities to propel your research forward. 🔗 https://lnkd.in/g23_R4A2 #celllinedevelopment #biopharmaceuticals #iQueInstrument #ResearchandDevelopment #DrugDiscovery #Biotech #Innovation #Sartorius #laboratory #lifesciences #assaydevelopment #pharmaceuticalindustry #pharma #drugmanufacturing

Fascinating analysis from Ed Saltzman. In the current environment, it is time for #biotechs to rethink exit strategies and prioritize current resources to derisk commercial #risks, especially for novel/complex modalities. Novel technology platforms should also focus on demonstrating agile #CMC production process to increase incentives for partnering. However, self-commercialization should also be on the table regarding next steps. #drugdevelopment #biotech #investor #partnering #businessdevelopment #riskassessment

Slides from the recent keynote "Biopharma Dealmaking: Time for a Re-Think" I delivered at the Swiss Healthcare Licensing Group meeting in Montreux in May are now available on the Lumanity website. https://lnkd.in/ePi9Vwse This data rich presentation is important viewing for anyone involved with or interested in biotech corp dev strategy but especially for those pre-commercial biotech "sellers" pinning their hopes on a large pharma partnership. The historically unprecedented increase in the number of biotechs reaching or surpassing clinical PoC stage (5 x or greater over past decade) coupled with a limited number of large pharma "buyers" means odds for vast majority of would be sellers are long. Many more of these biotechs should start to see self-commercializing, especially those pursuing advanced therapeutic modalities, such as cell and gene therapy, as more of a "Plan A" than B. And for many of these companies the time to get started is now, not when they are late in P3 or beyond.

Molecular Diagnostics Market Anticipated to reach $26.8 billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://lnkd.in/gyRmwtCD The size of global molecular diagnostics market in terms of revenue was estimated to be worth $15.6 billion in 2023 and is poised to reach $26.8 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028. 𝐌𝐚𝐢𝐧 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Roche Diagnostics Nederland Thermo Fisher Scientific QIAGEN Abbott Danaher Corporation Hologic, Inc. BD Siemens Healthineers Myriad Genetics Illumina Cepheid Grifols Diasorin bioMérieux Genomic Health MESO SCALE DIAGNOSTICS, LLC. Luminex Guardant Health Exact Sciences Natera Invitae Veracyte, Inc. Agena Bioscience Agilent Technologies Fluidigm Sciences, Inc. PerkinElmer Sysmex Corporation Ortho Clinical Diagnostics

𝐈𝐧 𝐕𝐢𝐭𝐫𝐨 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 (𝐈𝐕𝐃) 𝐑𝐞𝐚𝐠𝐞𝐧𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: 2024-2031 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 & 𝐓𝐫𝐞𝐧𝐝𝐬 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐃𝐞𝐦𝐨 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐄𝐱𝐜𝐞𝐥 𝐏𝐢𝐯𝐨𝐭 𝐚𝐧𝐝 𝐓𝐨𝐂: https://lnkd.in/dEDVxF9z #InVitroDiagnostic (IVD) #Reagents Market Size is valued at USD 76.10 Bn in 2023 and is predicted to reach USD 113.15 Bn by the year 2031 at a 5.21% CAGR during the forecast period for 2024-2031. ▪ 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐫𝐞: ▪ Thermo Fisher Scientific ▪ Becton, Dickinson and Company ▪ Bio-Rad Laboratories ▪ Agilent Technologies, Inc. ▪ QIAGEN ▪ Merck KGaA, Darmstadt, Germany ▪ Beckman Coulter Diagnostics ▪ Hologic, Inc. ▪ Abcam ▪ Bio-Techne ▪ InBios International, Inc. ▪ SDIX LLC - An OriGene Company ▪ RayBiotech. ▪ Sino Biological, Inc. #DiagnosticsMarket #MedicalResearch #Immunoassay #MolecularDiagnostics #MarketForecast 

Check out my recent Q&A interview!

In Vitro Diagnostics Market worth $119.4 billion by 2029 Download PDF Brochure:-https://lnkd.in/dqn9PmeT The global in vitro diagnostics market in terms of revenue was estimated to be worth $85.2 billion in 2024 and is poised to reach $119.4 billion by 2029, growing at a CAGR of 6.9% from 2024 to 2029. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Roche Diagnostics UK & Ireland Danaher Corporation Abbott Siemens Healthineers Sysmex Corporation Thermo Fisher Scientific, Becton, Dickinson and Company bioMérieux Bio-Rad Laboratories, Agilent Technologies, QIAGEN QuidelOrtho Diasorin Illumina, Hologic, Inc. Revvity Werfen Devyser Chembio Diagnostics, Inc. Surmodics, Inc. Menarini Silicon Biosystems SpeeDx Pty Ltd GENSPEED Biotech Accelerate Diagnostics, Merck Caris Life Sciences, Cellabs Epitope Diagnostics, Inc. Boster Biological Technology Enzo Biochem Inc Genetic Signatures Savyon Diagnostics Trivitron Healthcare mdxhealth Creative Diagnostics InBios International, Inc. Maccura Vela Diagnostics ARKRAY,Inc., #invitrodiagnostics #ivd #medicaldiagnostics #labtesting #healthcareinnovation

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market, but where does the multi-billion- dollar molecular diagnostic market stand post pandemic? Kalorama's "The World Market for Molecular Diagnostics, 12th Edition" has the insights you need. Get a glimpse of what’s included in this insights-packed report by downloading the table of contents here: https://hubs.la/Q02f0fbn0 Companies profiled in this report include: Bio-Rad Laboratories, CareDx, Inc., Exact Sciences, GenMark Diagnostics, Grifols, Hologic, Inc., Illumina, Meridian Bioscience Inc., NanoString Technologies, Inc., Revvity and more!

Interested in how cellular target engagement is transforming #drugdiscovery? Explore the capabilities of NanoBRET® Target Engagement Technology in an expert interview with Amy Landreman, Senior Product Manager at Promega. Discover how this advanced technology combines the precision of biochemical assays with the complexities of cellular contexts to revolutionize drug discovery. Don’t miss these essential insights—dive in now: https://bit.ly/3X5oP1U

Sepsis Diagnostics Market Worth $890 Million Download a PDF Brochure: https://lnkd.in/dMXnZeK7 Sepsis Diagnostics Market By Technology (Microbiology, PCR, Immunoassay, microfluidics, Biomarker), Product (Media, Reagent, Instrument), Method (Automated), Test (Lab, POC), Pathogen (Bacterial, Fungal), End User & Region - Global Forecast to 2029 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia) Other Companies that are Operating in this Market Globally: Cytovale Inflammatix, Inc. Selux Diagnostics, Inc Hansa Biopharma  QuantuMDx AusDiagnostics DNA Electronics (DNAe) #SepsisDiagnostics #SepsisAwareness #SepsisTesting #RapidSepsisDetection #BiomarkerTesting #BloodCultureTesting #MolecularDiagnostics #PointOfCareTesting #SepsisManagement #AntimicrobialStewardship